AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

AbbVie (NYSE:ABBV) will report Q4 2024 results ... meaning the upside to expectations comes from the existing and long-lived branded products and not because Humira is holding up better than ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie has been named a Top Socially Responsible ... considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its ...

AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...

AbbVie cautions that these forward-looking statements ... competition from other products, difficulties inherent in the research and development process, adverse litigation or government action ...

AbbVie's underlying business remains strong, and so does its dividend program. The company is a Dividend King with 52 ...

the immune-disease drug that was once Abbvie's top-selling product, as well as slowing sales of the company's aesthetic products such as Botox.

Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...

Pharmaceutical powerhouse AbbVie(NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while raising ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...